Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-07-31

Study Completion Date

2023-01-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of myelodysplastic cells, either by killing the cells or by stopping them from dividing. Tretinoin and decitabine may help myelodysplastic cells become more like normal cells, and to grow and spread more slowly. Giving decitabine together with tretinoin may be an effective treatment for myelodysplastic syndromes.

PURPOSE: This phase I/II trial is studying the side effects and best dose of tretinoin when given together with decitabine in treating patients with myelodysplastic syndromes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer

NCT00006239

Leukemia Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Diseases

COMPLETED PHASE1

Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia

NCT00671697

Myelodysplastic Syndromes and Leukemia, Myeloid, Acute

COMPLETED PHASE1

Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation

NCT02634827

Acute Myeloid Leukemia With FLT3/ITD Mutation Acute Myeloid Leukemia With Gene Mutations FLT3 Tyrosine Kinase Domain Point Mutation +2 more

TERMINATED PHASE2

Decitabine for Myelodysplastic Syndromes and Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation

NCT01806116

Higher-risk Myelodysplastic Syndrome Relapsed /Refractory Acute Myeloid Leukemia

UNKNOWN PHASE4

Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm

NCT02121418

Chronic Myelomonocytic Leukemia-2 Myelodysplastic Syndrome Myeloproliferative Neoplasm +1 more

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* Determine the hematologic and nonhematologic toxicities of decitabine in combination with tretinoin in patients with myelodysplastic syndromes. (Phase I)
* Determine the maximum tolerated dose of tretinoin when administered with decitabine in these patients. (Phase I)
* Determine the clinical remission rate (complete and partial remission) in patients treated with this regimen. (Phase II)
* Determine the rate of hematologic improvement in these patients. (Phase II)

Secondary

* Determine the efficacy of this regimen, in terms of improved bone marrow function, by monitoring frequency of transfusion, bleeding, and infection, as well as changes in bone marrow morphology and cytogenetics in these patients.
* Assess differentiation by morphology and flow cytometry and apoptosis by flow cytometry in patients treated with this regimen.
* Determine if gene expression changes in these patients are induced by this regimen.
* Determine the efficacy of this regimen, in terms of inducing demethylation of specific genes, in these patients.
* Correlate clinical response with gene expression, demethylation of specific genes, and flow cytometric indicators of differentiation and apoptosis.

OUTLINE: This is a phase I, dose-escalation study of tretinoin followed by a phase II, open-label study.

* Phase I: Patients receive decitabine IV over 1 hour once daily on days 1-5 followed by oral tretinoin twice daily on days 10-19. Treatment repeats every 28 days for a minimum of 4 courses in the absence of disease progression or excessive toxicity. Patients who achieve a partial or complete response after completing 6 courses of treatment may receive 4 additional courses up to a total of 10 courses. Patients with stable disease or hematologic improvement are removed from study.

Cohorts of 3-6 patients receive escalating doses of tretinoin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity attributable to tretinoin at any dose level during course 1. A total of 6 patients are treated at the MTD.

* Phase II: Patients receive decitabine as in phase I and tretinoin at the MTD. Patients undergo blood and bone marrow collection periodically during study for correlative demethylation and gene profiling studies and for evidence of differentiation and apoptosis. Samples are examined by flow cytometry, cytogenetics, histochemistry, and array-based whole genome methylation analysis.

After completion of study treatment, patients are followed at 30 days.

PROJECTED ACCRUAL: A total of 50 patients will be accrued for this study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myelodysplastic Syndromes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

* No decitabine-refractory disease defined as disease progression after discontinuation of therapy

* If previously treated with decitabine, must have responded to therapy (hematologic improvement or better per International Working Group Response Criteria)

PATIENT CHARACTERISTICS:

* Karnofsky performance status 60-100%
* Bilirubin ≤ 2.5 mg/dL
* AST and ALT ≤ 2 times upper limit of normal (ULN)
* Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No other medical condition that, in the opinion of the treating physician, would preclude patient compliance or put patient at excessive risk of treatment-related toxicity
* No other malignancy that would likely require systemic chemotherapy within 4 months after starting study treatment
* No allergy to parabens, vitamin A, or retinoids

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* Prior azacytidine allowed
* More than 4 weeks since prior cytotoxic chemotherapy or radiotherapy
* More than 4 weeks since prior experimental therapy
* Concurrent myeloid growth factors allowed only in the setting of febrile neutropenia according to established guidelines for use

Minimum Eligible Age

18 Years

Maximum Eligible Age

120 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No